The Headache Diseases Statistics Guide is a collaborative effort of the headache, migraine and cluster patient advocacy community. Its purpose is to streamline data about headache diseases, so that the information presented about these debilitating diseases is...
Building community and success 2021 was an impressive year of growth for the Coalition for Headache and Migraine Patients (CHAMP). As this report shows, we continued to build on our educational programs, expand our advocacy efforts, and substantially increase...
CHAMP is Proud to Celebrate Juneteenth CHAMP is proud to celebrate Juneteenth, an annual commemoration of the end of slavery in the United States after the Civil War. Although much progress has been made since June 19, 1865, systemic racism continues to exist shedding...
A child’s mind is no place for migraines As you know, migraine attacks can interfere with a person’s everyday life. And migraines in children can look differently from migraines in adults. This is why we wanted to make you aware of a research opportunity that you may...
Aly Raisman Sits Down with Katie Golden to Talk About Migraine Spotlights, flashing cameras, stress, neck pain, headaches, and fatigue. These symptoms and triggers were everyday occurrences for Olympic gold medalist Aly Raisman. She attributed it all to life as a...
After you’ve expressed interest in a clinical trial by contacting the trial team or filling out a pre-screener online, what comes next? Exact experiences vary, but your trial experience will most likely follow these steps: Phone screening: After you’ve found a...
Before a new treatment for migraine, cluster, or other headache diseases can reach patients, it must be approved by the Food and Drug Administration (FDA). The FDA evaluates results from clinical trials to determine whether a potential treatment is both safe and...
CHAMP Headache Disease Patient Access Survey, Briefs 1-3 The Coalition for Headache and Migraine Patients (CHAMP) recently conducted the Headache Disease Patient Access Survey (survey) to better understand the migraine and headache patient experience. The survey...
In 2018, a new class of medications was approved by the FDA for the prevention of migraine in adults. These drugs are referred to as calcitonin gene-related peptide (CGRP) inhibitors. There are currently multiple CGRP medications on the market. Dosing, frequency of...
The ECHO program provides training and community for the headache patient communicators that moderate online headache communities and create headache-focused content. By connecting and investing in the people that are leading and contributing communications, this...
